<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain><z:hpo ids='HP_0011010'>Chronic</z:hpo> <z:e sem="disease" ids="C1695782" disease_type="Disease or Syndrome" abbrv="">cerebral hypoperfusion</z:e> can cause learning and <z:hpo ids='HP_0002354'>memory impairment</z:hpo> and neuronal damage resembling the effects observed in vascular <z:hpo ids='HP_0000726'>dementia</z:hpo> </plain></SENT>
<SENT sid="1" pm="."><plain>PPAR-γ <z:chebi fb="4" ids="48705">agonists</z:chebi> were shown to modulate <z:mp ids='MP_0001845'>inflammatory response</z:mp> and neuronal <z:hpo ids='HP_0011420'>death</z:hpo> following <z:hpo ids='HP_0002637'>cerebral ischemia</z:hpo> </plain></SENT>
<SENT sid="2" pm="."><plain>The present study was designed to evaluate possible neuroprotective effects of <z:chebi fb="0" ids="50122">rosiglitazone</z:chebi>, a PPAR-γ <z:chebi fb="4" ids="48705">agonist</z:chebi>, in rat model of <z:hpo ids='HP_0011010'>chronic</z:hpo> <z:e sem="disease" ids="C1695782" disease_type="Disease or Syndrome" abbrv="">cerebral hypoperfusion</z:e> </plain></SENT>
<SENT sid="3" pm="."><plain><z:e sem="disease" ids="C1695782" disease_type="Disease or Syndrome" abbrv="">Cerebral hypoperfusion</z:e> was induced by permanent bilateral occlusion of the common carotid arteries </plain></SENT>
<SENT sid="4" pm="."><plain>Oral administration of <z:chebi fb="0" ids="50122">rosiglitazone</z:chebi> (1.5, 3, and 6 mg/kg/day) or vehicle was carried out for 5 weeks, starting one week before the surgery </plain></SENT>
<SENT sid="5" pm="."><plain>Cognitive performance was assessed using the <z:mp ids='MP_0001465'>Morris water maze</z:mp> </plain></SENT>
<SENT sid="6" pm="."><plain>The density of S100B protein-immunoreactive astrocytes and the OX-42-labeled microglial activation were estimated </plain></SENT>
<SENT sid="7" pm="."><plain>Synaptogenesis was also evaluated by the measurement of synaptophysin, the pre-synaptic vesicular protein, level via western blotting technique </plain></SENT>
<SENT sid="8" pm="."><plain><z:e sem="disease" ids="C1695782" disease_type="Disease or Syndrome" abbrv="">Cerebral hypoperfusion</z:e> for 30 days induced a significant <z:hpo ids='HP_0100543'>cognitive impairment</z:hpo> along with hyperactivation of both microglial and astroglial cells, and reduction of synaptophysin level </plain></SENT>
<SENT sid="9" pm="."><plain><z:chebi fb="0" ids="50122">Rosiglitazone</z:chebi> treatment (3 and 6 mg/kg) not only suppressed the activation of astrocytes and microglia markedly but also alleviated the impairment of memory and increased the synaptophysin level </plain></SENT>
<SENT sid="10" pm="."><plain>In conclusion, our results suggest that the <z:hpo ids='HP_0011010'>chronic</z:hpo> administration of <z:chebi fb="0" ids="50122">rosiglitazone</z:chebi> significantly prevents <z:hpo ids='HP_0011010'>chronic</z:hpo> <z:e sem="disease" ids="C1695782" disease_type="Disease or Syndrome" abbrv="">cerebral hypoperfusion</z:e>-induced brain damage, at least, partly through suppressing glial activation and preserving synaptic plasticity </plain></SENT>
<SENT sid="11" pm="."><plain>Thus, it appears that <z:chebi fb="0" ids="50122">rosiglitazone</z:chebi> may be a promising pharmacological agent in the development of therapeutic approaches for the prevention or treatment of cerebrovascular diseases </plain></SENT>
</text></document>